23637-93-6

Upstream product

• 18046-77-0 (11S,13S,17S)-17-Hydroxy-11,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one 
• 13667-06-6 11β-Methylestrone 
• 64109-64-4 (8S,9S,10R,11S,13S,14S,17S)-17-Hydroxy-10,11,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one 
• 17262-12-3 (8S,13S,14S)-3-Benzyloxy-11,13-dimethyl-6,7,8,12,13,14,15,16-octahydro-cyclopenta[a]phenanthren-17-one 
• 64143-38-0 C₂₇H₃₀O₄ 
• 64109-71-3 (8S,9S,10R,11S,13S,14S)-10,11,13-Trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-6H-cyclopenta[a]phenanthrene-3,17-dione 
• 64109-67-7 (8S,9S,11S,13S,14S)-3-Benzyloxy-11-hydroxy-11,13-dimethyl-6,7,8,9,11,12,13,14,15,16-decahydro-cyclopenta[a]phenanthren-17-one 
• 1071830-88-0 C₃₃H₃₈O₂ 

Relevant academic research and scientific papers

Synthesis of substituted estradiols by the selective aromatization of A-ring of steroidal 19-nor-Δ-4-3-ketones with phenylselenyl halides/hydrogen peroxide

A range of 6-, 7-, and 11-substituted estradiols were synthesized by the selective aromatization of the A-ring of 19-nor steroids using phenylselenyl halides followed by oxidation with hydrogen peroxide. Established methods utilizing copper(II) halides failed or have given poor yields with these substrates.

17ALPHA-SUBSTITUTED STEROIDS AS SYSTEMIC ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS

Compounds having the structure, their salts or N-oxide derivatives: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

STRUCTURE-ACTIVITY RELATIONSHIPS OF ESTROGENS, EFFECTS OF 14-DEHYDROGENATION AND AXIAL METHYL GROUPS AT C-7, C-9 AND C-11

Thirty compounds were evaluated in the rat for uterotropic effects, inhibition of gonadotropin release, and competitive displacement of (3H) estradiol-17β from uterine cytosolic preparations. 7α-Methylestradiol-17β was 150percent as active as estradiol-17β as an uterotropic agent.Estradiol-17β was the most active inhibitor of gonadotropin release. 11β-Methylestradiol-17β had 124percent of the activity of estradiol-17β in displacing (3H) estradiol-17β from the "estrogen receptor." The 9α-methyl group considerably decreased the potency of estrogens in any of the three assays.The 14-dehydromodification was advantageous only in the estradiol-17β 3-methyl ether series.Uterotropic activities and inhibition of gonadotropin release did not parallel.The best compound for inhibiting gonadotropin release, as compared to uterotropic activity, was estrone.The "estrogen receptor" assay data correlated fairly well with uterotropic assay data, but only for compounds having free 3-hydroxyl groups; even so, some exceptions were noted.